INTS

2.4551.80%
LH

Lewis H. Bender

Founder, President, CEO & Chairman of the Board

Mr. Lewis H. Bender, also known as Lew, M.S., M.A., M.B.A., is the Founder of Intensity Therapeutics, Inc. and serves as its Chief Executive Officer and President since April 2012 and also serves as its Chairman of the Board. Mr. Bender served as the Chief Executive Officer of Interleukin Genetics, Inc. from January 23, 2008 to August 23, 2012. Mr. Bender served as Principal Financial Officer of Interleukin Genetics, Inc. until April 30, 2008 and served as its Principal Accounting Officer. He served as Chief Executive Officer and President of Emisphere Technologies Inc. since January 12, 2007 and served as its Interim Chief Executive Officer and President. While at Emisphere from 1993 to December of 2007 he held various positions. He served as Chief Technology Officer of Emisphere Technologies, Inc. and was responsible for managing the technical operations. He also served as Senior Vice President of Business Development and Vice President of Manufacturing and Process Development at Emisphere Technologies Inc. since April 1997 and served as its Vice President of Business Development since October 1995. Previously, Mr. Bender served as Director of Business Development of Emisphere Technologies Inc., where he joined in 1993. He was responsible for the establishment of an international joint venture with Elan Corporation and he served as the Lead Negotiator for significant license agreements with Eli Lilly, Novartis Pharma AG, and Roche Pharmaceuticals. Prior to Emisphere, Mr. Bender served as General Manager of the specialty chemicals division at Metalor SA, in Neuchatel, Switzerland. In addition, he served as Production Planning Specialist for pharmaceutical manufacturing at Roche Pharmaceuticals. Mr. Bender has over 22 years of biotech and pharmaceutical experience having led teams taking products from discovery to Phase III for compounds using novel drug delivery techniques. In addition, he has been successful in raising (or helping to raise) capital with institutional investors using several vehicles such as registered direct placements, PIPES, S-3 & S-1 filings, and convertible debt. He concluded over 60 research collaboration agreements with pharmaceutical and biotechnology companies. Mr. Bender served as a Director of Interleukin Genetics, Inc. from July 2008 to August 23, 2012. Mr. Bender received a BS & an MS in Chemical Engineering from the Massachusetts Institute of Technology, an MA in International Studies from the University of Pennsylvania and an MBA from the Wharton School of the University of Pennsylvania.

Positions